Heidelberg Pharma AG:
Heidelberg Pharma AG (WL6, Frankfurt Stock Exchange), based in Ladenburg, Germany, is a leading biotech company pioneering the use of its ATAC (Antibody Targeted Amanitin Conjugate) platform to develop novel cancer treatments with a unique mode of action effective at specifically killing both inactive and dividing cancers cells and overcoming tumour resistance mechanisms. The platform can be applicable across many cancer types and has a specific genetic biomarker that confers high tumour cell susceptibility to the therapy in many cancer types. Heidelberg Pharma is accelerating development of an internal pipeline of ATACs. Lead product HDP-101, for blood cancer, is expected to enter phase I studies by end 2020. It also has several out-licensed programs using ATAC and antibody drug conjugate technology expected to generate long term income streams and early technology validation
Immuno-Oncology, Men's Health
100MM - 500MM
Schriesheimer Straße 101
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Top 10 Holders of Heidelberg Pharma AG
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by